I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. I-Mab stands second among them.

I-Mab (NASDAQ:IMAB) is a U.S.-based biotechnology company focused on precision immuno-oncology, developing differentiated therapies for cancer. Its lead candidate, givastomig, is a bispecific antibody targeting Claudin 18.2 and 4-1BB, designed to selectively activate T cells within the tumor microenvironment, aiming to maximize anti-tumor effects while reducing common toxicities of other 4-1BB agents.

In September 2025, the corporation participated in major investor conferences, including the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference, where it showcased its strategic vision and pipeline progress.

Key clinical progress includes positive Phase 1b dose escalation results for givastomig in combination with immunochemotherapy for first-line metastatic gastric cancer, presented at the ESMO GI 2025 conference. The data revealed an impressive 83% objective response rate at doses selected for expansion. Enrollment in the Phase 1b expansion cohorts was completed ahead of schedule, with topline results expected in the first quarter of 2026, highlighting strong tumor-binding and anti-tumor activity.

I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer

Financially, I-Mab (NASDAQ:IMAB) bolstered its resources with an August 2025 underwritten offering raising approximately $61.2 million, bringing its pro-forma cash balance to $226.8 million as of June 30, 2025. This robust capital position is expected to fund operations through late 2028, supporting ongoing clinical development and further pipeline advancement.

While we acknowledge the risk and potential of IMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IMAB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.